The Clinical Trial Awards (CTA) Program funded by the ALS Association offers funding for investigators in industry or academia worldwide. This funding is for researchers focused on clinically testing novel or repositioning approaches for Amyotrophic Lateral Sclerosis (ALS).
This funding provides up to $1,000,000 USD total costs to be allocated over two or three years, with indirect costs limited to 10%.
- Budgets for direct and indirect costs up to $1,000,000 USD:
- 2-year project – First year: $500,000; Second year: $500,000
- 3-year project – First year: $500,000; Second year: $250,000; Third year: $250,000
This year, a letter of intent is due on May 17, 2023. Full applications are by invitation only and due on August 2, 2023.